SARS-CoV-2 seroprevalence among parturient women in Philadelphia.

TitleSARS-CoV-2 seroprevalence among parturient women in Philadelphia.
Publication TypeJournal Article
Year of Publication2020
AuthorsFlannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, Gerber JS, Arevalo CP, Bolton MJ, Weirick ME, Goodwin EC, Anderson EM, Greenplate AR, Kim J, Han N, Pattekar A, Dougherty J, Kuthuru O, Mathew D, Baxter AE, Vella LA, Weaver JE, Verma A, Leite R, Morris JS, Rader DJ, Elovitz MA, E Wherry J, Puopolo KM, Hensley SE
JournalSci Immunol
Volume5
Issue49
Date Published2020 Jul 29
ISSN2470-9468
Abstract

Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important for determining SARS-CoV-2 exposures within both individuals and populations. We validated a SARS-CoV-2 spike receptor binding domain serological test using 834 pre-pandemic samples and 31 samples from COVID-19 recovered donors. We then completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate exposure to SARS-CoV-2 within the community.

DOI10.1126/sciimmunol.abd5709
Alternate JournalSci Immunol
PubMed ID32727884